Articles related to Urology

In the phase 3 GETUG-AFU 18 trial, high-dose radiotherapy (80 Gy) combined with long-term androgen deprivation therapy markedly improved 10-year progression-free and overall survival in high-risk prostate cancer patients, without additional toxicity.

In a rigorously designed trial involving more than 5,000 participants, researchers observed that testosterone treatment in hypogonadal men aged 45-80 was associated with a 1.43 times higher risk of clinical fractures compared to placebo. These findings are crucial in re-evaluating the therapeutic approach to testosterone replacement in this demographic.

In a landmark study, researchers found that each doubling of PSA levels in men over 70 doubles the risk of prostate cancer death, highlighting the critical need for tailored screening approaches in older patients.

In a novel approach to combat metastatic castration-resistant prostate cancer, ODM-208, targeting cytochrome P450 11A1, has shown promising results in reducing prostate-specific antigens and testosterone levels, offering new hope in a challenging therapeutic area.

In a recent high-profile case, a jury awarded over $2 million in a robot-assisted prostate surgery lawsuit, underlining the critical importance of surgical precision and accountability in advanced medical procedures.

In a significant shift, a new phase 3 trial suggests reconsidering adjuvant radiotherapy after radical prostatectomy, as many patients may not require it long-term, potentially reducing morbidity risks.